163837-49-8 ((Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, (-)-)

快速询单

结构式：

Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, (-)-MOL文件

CAS号：

163837-49-8

英文名称：

Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, (-)-

分子式：

C₂₅H₂₇ClN₂

分子量：

390.948285341263

Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, (-)-(163837-49-8)名称与标识符

名称

英文别名：

Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, (-)-;

标识符

InChIKey：

OCJYIGYOJCODJL-UHFFFAOYSA-N

Inchi：

1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3

SMILES：

N1(C(C2=CC=C(Cl)C=C2)C2=CC=CC=C2)CCN(CC2=CC=CC(C)=C2)CC1

Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, (-)-(163837-49-8)物化性质

实验特性

沸点 : 495.3±40.0 °C(Predicted)
酸度系数(pKa) : 6.73±0.10(Predicted)
密度 : 1.159±0.06 g/cm3(Predicted)

Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, (-)-(163837-49-8)推荐厂家更多厂家(1)

公司名称	手机号/电话	联系人	QQ	微信	询单
湖北扬信医药科技有限公司	13092795037 0714-3996388	熊磊	3003473323		询单

Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-, (-)-(163837-49-8)相关文献

1. Simultaneous determination of antihistamine anti-allergic drugs, cetirizine, domperidone, chlorphenamine maleate, loratadine, meclizine and buclizine in pharmaceutical formulations, human serum and pharmacokinetics application
Nawab Sher,Farhan Ahmed Siddiqui,Najmul Hasan,Nighat Shafi,Arif Zubair,Agha Zeeshan Mirza Anal. Methods 2014 6 2704
2. Chiral separation of five antihistamine drug enantiomers and enantioselective pharmacokinetic study of carbinoxamine in rat plasma by HPLC-MS/MS
Meng Li,Junyuan Zhang,Siman Ma,Zhen Jiang,Xin Di,Xingjie Guo New J. Chem. 2020 44 5819
3. Disposable screen-printed electrodes modified with uniform iron oxide nanocubes for the simple electrochemical determination of meclizine, an antihistamine drug
Ahmed A. Khorshed,Mohamed Khairy,Sherif A. Elsafty,Craig E. Banks Anal. Methods 2019 11 282
4. Prescribed drugs containing nitrogen heterocycles: an overview
Majid M. Heravi,Vahideh Zadsirjan RSC Adv. 2020 10 44247
5. Programmable iodization/deuterolysis sequences of phosphonium ylides to access deuterated benzyl iodides and aromatic aldehydes
Yu Zheng,Xian-Chen He,Jie Gao,Zhen-Zhen Xie,Zhi-Wei Wang,Zhi-Lin Liu,Kai Chen,Hao-Yue Xiang,Xiao-Qing Chen,Hua Yang Chem. Commun. 2022 58 4215
6. Green corrosion inhibitors for aluminium and its alloys: a review
Klodian Xhanari,Matja? Fin?gar,Ma?a Knez Hrn?i?,Uro? Maver,?eljko Knez,Bujar Seiti RSC Adv. 2017 7 27299
7. Visible light photocatalysis in the late-stage functionalization of pharmaceutically relevant compounds
Rolando Cannalire,Sveva Pelliccia,Luca Sancineto,Ettore Novellino,Gian Cesare Tron,Mariateresa Giustiniano Chem. Soc. Rev. 2021 50 766
8. Droplet microarray: miniaturized platform for rapid formation and high-throughput screening of embryoid bodies
Tina Tronser,Konstantin Demir,Markus Reischl,Martin Bastmeyer,Pavel A. Levkin Lab Chip 2018 18 2257
9. Development and validation of an EI-GC-MS method for the determination of 11 antihistamines in whole blood. Applications in clinical and forensic toxicology
Maria Katselou,Sotiris Athanaselis,Panagiota Nikolaou,Samir Qammaz,Maria Stefanidou,Chara Spiliopoulou,Ioannis Papoutsis Anal. Methods 2018 10 4926
10. Chiral 1,1-diaryl compounds as important pharmacophores
Dana Ameen,Timothy J. Snape Med. Chem. Commun. 2013 4 893